A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults

Antiviral Therapy

Volumn 8, Issue 4, 2003, Pages 279-287

  Lalezari, Jacob P ^a   DeJesus, Edwin ^b   Northfelt, Donald W ^c   Richmond, Gary ^q   Wolfe, Peter ^d   Haubrich, Richard ^e   Henry, David ^f   Powderly, William ^g   Becker, Stephen ^h   Thompson, Melanie ⁱ   Valentine, Fred ^j   Wright, David ^k   Carlson, Margrit ^l   Riddler, Sharon ^m   Haas, Frances F ⁿ   DeMasi, Ralph ^o   Sista, Prakash R ^o   Salgo, Miklos ^p   Delehanty, John ^o  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IDC Research Initiative   (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

^d Pacific Oaks Medical Group   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Pennsylvania Oncology Hematology Associates   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Pacific Horizon Medical Group   (United States)

ⁱ ARCA   (United States)

^j NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^k Central Texas Clinical Research   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁿ Assoc in Med/Mental Health PC   (United States)

^o Trimeris Inc   (United States)

^p HOFFMANN LA ROCHE INC   (United States)

^q NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; CD4 ANTIGEN; EFAVIRENZ; ENFUVIRTIDE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL ABSCESS; ABNORMAL DREAM; ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL FUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DERMATITIS; DIARRHEA; DISORIENTATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; GENOTYPE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; HYPESTHESIA; IMMUNE COMPLEX DISEASE; IMMUNOREACTIVITY; INJECTION PAIN; INJECTION SITE; INSOMNIA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SUBCUTANEOUS NODULE; VERTIGO; VIRUS ADSORPTION; VIRUS LOAD; VIRUS TITRATION; VIRUS TYPING;

ADULT; ANTI-HIV AGENTS; CARBAMATES; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OXAZINES; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 10744229122     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Mocroft A, Katlama C, Johnson AM, Pradier C, Antunes F, Mulcahy F, Chiesi A, Phillips AN, Kirk O & Lundgren JD. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291-296.
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998;338:853-860.
3. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG & Volberding PA. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel, Journal of the American Medical Association 2000; 283:381-390.
4. Shafer RW, Winters MA, Palmer S & Merigan TC. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Annals of Internal Medicine 1998; 128:906-911.
5. Gerber JG. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection. Clinical Infectious Diseases 2000; 30(Suppl. 2):8123-8129.
6. Flexner C. HIV-protease inhibitors. New England Journal of Medicine 1998; 338:1281-1292.
7. Mitsuya H, Yarchoan R & Broder S. Molecular targets for AIDS therapy. Science 1990; 249:1533-1544.
8. Montaner JS & Mellors JW. Antiretroviral therapy for previously treated patients. New England Journal of Medicine 2001; 345:452-455.
9. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J & Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393:648-659.
10. Chan DC, Fass D, Berger JM & Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997; 89:263-273.
11. Veronese FD, DeVico AL, Copeland TD, Oroszlan S, Gallo RC & Sarngadharan MG. Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 1985; 229:1402-1405.
12. Wild C, Greenwell T & Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Research & Human Retroviruses 1993; 9:1051-1053.
13. Wild CT, Shugars DC, Greenwell TK, McDanal CB & Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proceedings of the National Academy of Sciences, USA 1994; 91:9770-9774.
14. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM & Saag MS. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nature Medicine 1998; 4:1302-1307.
15. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F, Saag MS, Nelson EL, Sista PR & Dusek A. The safety, plasma pharmacokinetics and antiviral activity of subcutaneous T-20, a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Research & Human Retroviruses 2002; 18:685-693.
16. Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC & Powderly WG. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Annals of Internal Medicine 1995; 122:24-32.
17. Wheat LJ, Lalezari J, Kilby M, Wheeler D, Salgo M, DeMasi R & Delehanty J. A week-48 assessment of high strength T-20 formulations in multi-class experienced patients. 9th Conference on Retroviruses & Opportunistic Infections. Seattle, Wash., USA, 24-28 February 2002; Abstract 417-W.
18. Tomaras GD & Greenberg ML. Mechanisms for HIV-1 entry: current strategies to interfere with this step. Current Infectious Disease Reports 2001; 3:93-99.
19. Tremblay CL, Kollmann C, Giguel F, Chou TC & Hirsch MS. Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4 blocker AMD-3100. Journal of Acquired Immune Deficiency Syndromes 2000; 25:99-102.
20. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T & Olson WC. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. Journal of Infectious Diseases 2001; 183:1121-1125.
21. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R & Back DJ. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001; 15:675-681.
22. Profit L, Eagling VA & Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999; 13:1623-1627.